U.S. pharmaceutical industry is studied

Oct 12, 2006

A new study concludes the U.S. pharmaceutical industry might be wasting more than $50 billion every year in manufacturing expenses.

The finding is part of the largest empirical study ever performed of pharmaceutical manufacturing and the U.S. Food and Drug Administration's monitoring policies.

The study was conducted by Jackson Nickerson, professor of organization and strategy at Washington University in St. Louis, and Jeffrey Macher, assistant professor of strategy and economics at Georgetown University.

"We undertook the project to understand how the FDA regulates and pharmaceutical manufacturers produce, so we could see where there may be conflicts that inhibit advances in manufacturing," Nickerson said. "Our policy goal is to understand both sides of the coin so that we could contribute to improving the regulatory environment, thereby altering the pharmaceutical industry's incentives to maintain and in some cases enhance product quality but for a much lower cost."

The researchers collected data from 42 manufacturing facilities and determined companies extensively using information technology displayed superior manufacturing performance compared with other firms.

They also found the lower in the ranks a company allows employees to make decisions, the higher the company's overall manufacturing performance.

Copyright 2006 by United Press International

Explore further: Study reveals medical students believe health policy education is improving

add to favorites email to friend print save as pdf

Related Stories

Understanding active pharmaceutical ingredients

Jun 05, 2014

Active pharmaceutical ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The ...

Neutron beams reveal how antibodies cluster in solution

May 19, 2014

Scientists have used small-angle neutron scattering (SANS) and neutron spin-echo (NSE) techniques for the first time to understand how monoclonal antibodies (mAbs), a class of targeted biopharmaceuticals ...

Recommended for you

Face transplants change lives, identity

Jul 23, 2014

Patients are prepared to take significant risks in order to be considered for a face transplant, says Dr David Koppel, director of the largest craniofacial unit in the UK and Honorary Clinical Associate Professor ...

User comments : 0